Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Wegovy eligibility verification?
Prior authorization is the process of obtaining insurance approval before Wegovy or Zepbound can be dispensed. Over 88% of people with GLP-1 coverage still face PA requirements (GoodRx 2026). PA requirements for semaglutide and tirzepatide in Medicare Part D rose from under 15% to over 80% of plans in approximately one year (JAMA Network Open). This rapid escalation means practices that were approving these medications without PA a year ago are now seeing requirements on nearly every submission.
When Does the Workflow Start?
The workflow starts when the provider recommends one of these medications. For practices managing both drugs, it should start with a dual-drug eligibility check rather than assuming one drug is better positioned than the other.
Phase 1 — Eligibility Verification: Is this patient covered for anti-obesity medications? Does the plan cover Wegovy, Zepbound, or both? Are there employer-level exclusions that override the plan’s standard formulary? Many self-funded employer plans carve out weight-loss medications entirely, even when the insurance card shows a major payer like Aetna or UHC. The formulary shown on the payer portal may not reflect employer-level exclusions.
Phase 2 — Prior Authorization: Can the practice document that this patient meets the plan’s specific clinical criteria for this specific drug? The criteria are not the same for both medications, even on the same plan. Wegovy and Zepbound have different step therapy requirements, different documentation thresholds, and different alternate indication pathways.
Starting at Phase 2 without completing Phase 1 is the most common PA error in weight management billing. Practices that skip eligibility verification and go straight to PA submission waste days building documentation for a drug the patient’s plan does not cover. Both phases must complete on Day 1 of the workflow. Running eligibility first takes 10-15 minutes and prevents hours of wasted PA work downstream.
Step-by-Step Workflow for GLP-1 Prior Authorization
Step 1: Intake and Eligibility Pre-Screen (Day 1). Confirm clinical eligibility before verifying insurance. Required: current BMI (date-stamped within 90 days), ICD-10 codes (E66.01, E66.09, E66.9, plus applicable comorbidity codes), documentation of prior weight-loss attempts, current medication list, insurance card and PBM information.
Step 2: Verify Eligibility for BOTH Drugs (Day 1). Log into Availity or the payer portal. Verify active insurance status, PBM identity, whether anti-obesity medications are covered, formulary tier for each drug separately, PA and step therapy requirements, and quantity limits. If both drugs are excluded, identify whether alternate indications (CVD for Wegovy, OSA for Zepbound) create a pathway.
Step 3: Gather Clinical Documentation (Days 2-3). Core requirements: recent BMI records (within 90 days), comorbidity records with ICD-10 codes, lifestyle modification records (3-6 months), step therapy history, letter of medical necessity, prescriber NPI and credentials. Drug-specific additions: Wegovy CVD pathway requires cardiovascular documentation; Zepbound OSA pathway requires sleep study results and AHI score.
Step 4: Submit the Prior Authorization (Days 3-4). Submit via CoverMyMeds, Availity, Surescripts, manufacturer portals (NovoCare for Wegovy, Lilly Solutions Center for Zepbound), or direct payer portals. Submit with ALL documentation attached. Document submission method, date, confirmation number, and all attachments.
Step 5: Monitor and Follow Up (Days 5-15). Under CMS-0057-F, payers must respond within 7 calendar days (standard) or 72 hours (urgent). Check the portal daily. Respond to documentation requests within 24 hours. Notify the provider if a peer-to-peer review is offered.
Step 6: If Approved. Confirm approval number, start date, quantity, and coverage period. Coordinate with specialty pharmacy. Schedule a 3-month follow-up. Set a renewal alert 30 days before PA expiration.
Step 7: If Denied. Identify the denial category: drug class excluded, clinical criteria not met, step therapy incomplete, or administrative error. If one drug is denied and the other would qualify, file the appeal AND submit a new PA for the alternative drug simultaneously.
What Information Is Required for Both Drugs?
Universal requirements: BMI 30+ or BMI 27+ with qualifying comorbidity, current weight and BMI (within 60-90 days), ICD-10 codes for obesity and comorbidities, 3-6 months of lifestyle modification documentation, letter of medical necessity, prior medication history, prescriber NPI and credentials.
Payer-specific notes: Aetna requires 6 months lifestyle modification and BMI within 60 days. UHC may require BMI 40+ for Wegovy. CVS Caremark prefers Wegovy and requires step therapy through Wegovy before Zepbound. Medicare (current through June 2026): Wegovy covered only under CVD indication; Zepbound covered only under OSA indication. Starting July 2026, Medicare GLP-1 Bridge covers both for weight reduction at $50/month.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Why This Process Matters
MGMA 2025 data shows 92% of medical group practices have hired or reassigned staff for PA volume. The AMA reports 82% of physicians say PA leads to treatment abandonment. The CAQH 2024 Index estimates prior authorization costs the healthcare system approximately $35 billion annually.
For 2026 specifically: Pennsylvania Medicaid ended adult weight loss GLP-1 coverage January 1, 2026. CVS Caremark removed Zepbound from its standard formulary in July 2025. The Medicare GLP-1 Bridge launches July 2026.
GA, PA, IL: State-Specific Eligibility Rules for Wegovy and Zepbound
For practices in Georgia, Pennsylvania, and Illinois, the eligibility pre-screen must account for state-specific Medicaid coverage rules before any PA documentation is assembled. None of these three states cover Wegovy or Zepbound through Medicaid for the weight loss indication as of April 2026.
Georgia: Georgia Medicaid (administered through Amerigroup, CareSource, and Peach State MCOs) does not cover GLP-1 medications for obesity. Coverage may be available for the Type 2 diabetes indication under a different formulary pathway, but the obesity indication is excluded. Practices serving Georgia Medicaid patients should verify coverage for the diabetes indication separately if the patient has a qualifying comorbid diagnosis.
Pennsylvania: Pennsylvania Medicaid ended adult weight-loss GLP-1 coverage effective January 1, 2026. This was a significant policy change that caught many practices mid-authorization. Patients who had active Wegovy or Zepbound PAs under PA Medicaid before that date had their authorizations terminated. HealthChoices MCOs (AmeriHealth Caritas, Geisinger, Gateway, UPMC) followed the state policy. Practices must direct affected patients to manufacturer assistance programs (NovoCare for Wegovy, Lilly Solutions Center for Zepbound) or explore commercial coverage options.
Illinois: Illinois Medicaid does not cover GLP-1 medications for the weight loss indication. The Prior Authorization Reform Act (effective January 2025) applies to covered medications only, so its timeline protections (24-hour urgent, 5-day standard) do not help if the drug class is excluded from the formulary. Illinois MCOs may cover GLP-1 medications for Type 2 diabetes with appropriate PA documentation and ICD-10 coding for the diabetes indication.
How Staffingly Supports the Full GLP-1 PA Workflow
Staffingly provides trained PA specialists who manage the complete Wegovy and Zepbound PA workflow from eligibility pre-screen through reauthorization.
- Run dual-drug eligibility checks for BOTH drugs on every patient’s plan
- Build complete documentation packages to payer-specific criteria before first submission
- Submit via CoverMyMeds, Availity, payer portals, NovoCare, and Lilly Solutions Center
- Monitor PA status daily and respond to documentation requests within 24 hours
- Execute the dual-drug switch protocol when one medication is denied
- Initiate reauthorizations 30 days before expiration
- GA, PA, and IL state-specific coverage guidance
800+ providers. Starting at $399/week (volume discounts to $299/week), 70% savings. 99.2% clean claim rate. 48-72 hour go-live. SOC 2 Type II, HITRUST, ISO 27001, HIPAA compliant.
What Did We Learn?
Managing a comprehensive workflow for Wegovy eligibility verification and Zepbound prior authorization requires more than a single-drug checklist. The two most common errors, assuming formulary data covers employer plan exclusions and treating both drugs as identical for PA purposes, generate the most denials and rework. A practice that verifies eligibility for only one drug before submitting PA documentation wastes an average of 3-5 staff hours when that drug is denied and the process must restart for the alternative.
The practices with the highest approval rates share four habits. They verify eligibility for both drugs on every patient’s plan before selecting either medication. They build documentation to payer-specific criteria before the first submission rather than waiting for an information request. They respond to additional documentation requests from payers within 24 hours, keeping the review process moving. And they have a dual-drug switch protocol ready so that when one medication is denied, the appeal and the alternative PA submission happen simultaneously instead of sequentially.
The regulatory environment continues to shift. Pennsylvania ended adult GLP-1 Medicaid coverage in January 2026. CVS Caremark removed Zepbound from its standard formulary in July 2025. The Medicare GLP-1 Bridge launches July 2026, creating new coverage pathways that did not exist last year. Every one of these changes requires updating your eligibility pre-screen and your PA documentation workflow. Practices that treat GLP-1 PA as a static process will fall behind as payer rules continue to change quarterly. If your team is spending more than 20 hours per week on GLP-1 PA work across both drugs, consider outsourcing to a team like Staffingly that already tracks these payer changes in real time and maintains updated documentation templates for every major commercial plan, Medicare Part D, and state Medicaid program.
What People Are Asking
FAQ 1: Why do Wegovy and Zepbound require prior authorization? Both are high-cost GLP-1 medications. Payers require documented proof that the patient meets BMI, comorbidity, and lifestyle modification criteria. Over 88% of commercially insured people with GLP-1 coverage still face PA requirements.
FAQ 2: What is the difference between Wegovy and Zepbound for the PA workflow? Wegovy has an FDA-approved cardiovascular risk reduction indication (March 2024). Zepbound has an FDA-approved OSA indication (December 2024). Formulary placement also differs: CVS Caremark prefers Wegovy and requires step therapy through Wegovy before Zepbound.
FAQ 3: How long does the GLP-1 PA process take in 2026? Under CMS-0057-F, payers must respond within 7 calendar days (standard) or 72 hours (urgent). Most decisions arrive within 5-15 business days. Complete documentation on first submission produces the shortest turnaround.
FAQ 4: What do I do if Wegovy is denied and I want to try Zepbound? Document the denial reason. If caused by a drug class exclusion, Zepbound faces the same result unless an alternate indication (OSA) creates a separate pathway. If clinical criteria differ, file the appeal AND submit a new Zepbound PA simultaneously.
FAQ 5: Does Medicare cover Wegovy or Zepbound for weight loss? Not under standard coverage as of April 2026. Wegovy is covered only for CVD risk reduction. Zepbound is covered only for OSA. Starting July 2026, the Medicare GLP-1 Bridge covers both at $50/month for eligible beneficiaries.
FAQ 6: Do Georgia, Pennsylvania, and Illinois Medicaid cover these drugs for weight loss? None of the three states cover Wegovy or Zepbound through Medicaid for the weight loss indication as of April 2026. Pennsylvania ended adult GLP-1 weight loss coverage January 1, 2026. All three may cover GLP-1s for Type 2 diabetes indications.
FAQ 7: How often do Wegovy and Zepbound PAs need to be renewed? Most payers require reauthorization every 3-6 months. Renewal requires proof of clinical response (minimum 5% weight loss from baseline) and documented adherence. Track each drug’s PA expiration date separately. Set a 60-day advance reminder in your scheduling system to begin assembling renewal documentation before the authorization expires.
How Staffingly Manages the Dual-Drug GLP-1 Workflow
Managing eligibility verification and PA for two competing GLP-1 medications creates administrative complexity that most front-desk teams cannot sustain alongside their other responsibilities. When staff must check two formularies, compare two sets of PA criteria, and maintain documentation for two potential submissions per patient, the workload doubles while the margin for error increases.
Staffingly’s dedicated PA specialists handle the dual-drug workflow as their primary function. The process begins with a comprehensive eligibility check before drug selection. The specialist confirms plan coverage for both Wegovy and Zepbound, identifies benefit exclusions at the employer level, documents the PA criteria for each drug under the patient’s specific plan, and determines which drug and which indication pathway gives the highest probability of approval. This front-end work takes 15-20 minutes per patient but prevents hours of wasted effort on submissions that were destined for denial.
When one drug is denied, the specialist does not wait for the appeal to resolve before starting the alternative pathway. The appeal and the new PA submission proceed simultaneously, cutting the total time to medication access by 50% compared to a sequential approach where staff waits for the appeal outcome before considering the alternative.
Staffingly maintains payer-specific PA playbooks for both drugs, updated continuously as formularies change. When CVS Caremark dropped Zepbound in July 2025, when Pennsylvania Medicaid ended adult GLP-1 coverage in January 2026, and when the Medicare GLP-1 Bridge announced its July 2026 launch, the playbooks were updated the same week.
99.2% clean claim rate. 800+ providers served. Starting at $399/week (volume discounts to $299/week) with 70% savings versus in-house PA staffing. 48-72 hour go-live with integration into 50+ EHR platforms. SOC 2 Type II, HITRUST, ISO 27001, and HIPAA compliant. Book A Strategy Call or start a 15-Day Risk-Free Pilot.
